Last reviewed · How we verify
PEG-rhGH low dose
At a glance
| Generic name | PEG-rhGH low dose |
|---|---|
| Also known as | Polyethylene Glycol Recombinant Human Somatropin Injection |
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature (PHASE2)
- Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature (PHASE2)
- A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome (PHASE2)
- A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature (PHASE2)
- Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency (PHASE4)
- Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-rhGH low dose CI brief — competitive landscape report
- PEG-rhGH low dose updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI